Rifaximin Predicts the Complications of Decompensated Cirrhosis

• Status: Unknown status
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Cirrhotic patients are predisposed to intestinal dysmotility, bacterial overgrowth, and increased intestinal permeability all leading to an increase in bacterial translocation and increased endotoxemia. Rifaximin is an antibiotic that is virtually non-absorbed after oral administration and exhibits broad spectrum antimicrobial activity against both aerobic and anaerobic gram-positive and gram-negative microorganisms within the gastrointestinal tract. It has been suggested that oral prophylactic antibiotics or bowel decontamination might improve long-term outcomes in patients with cirrhosis. The aim of this study was to explore the suitable dose of rifaximin to alleviate endotoxemia and prevent the complications of advanced cirrhosis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Changzheng Hospital
• Treatments: Rifamycins; Rifaximin

Criteria

Inclusion Criteria:

• Decompensated cirrhosis

• Child-Pugh B or C stage

Exclusion Criteria:

• severe complications of cirrhosis in the past one month.

• renal dysfunction.

• administration of antibiotics in the past two weeks.

• malignant tumors.

• HIV infection.

• severe heart and lung disease

• sensitivity to rifaximin

• Pregnancy and lactation woman

• Patients who have took part in other clinical trials in the past three months.